Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -64.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 700
Avg Vol 6,474
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 71%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chroni...

Phone: 650 549 1400
Address:
2200 Bridge Pkwy, Suite 102, Redwood City, United States
Latest News on JSPRW
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

2026-03-30T20:37:13.000Z - 6 weeks ago

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)


Jasper Therapeutics assumed with a Neutral at UBS

2026-03-23T10:20:58.000Z - 7 weeks ago

Jasper Therapeutics assumed with a Neutral at UBS


Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

2026-01-13T20:20:15.000Z - 4 months ago

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw


Jasper Therapeutics Transcript: Study Result

Jan 8, 2026, 8:00 AM EST - 4 months ago

Jasper Therapeutics Transcript: Study Result


3 Penny Stocks to Watch Now, 12/4/25

2025-12-04T16:57:00.000Z - 5 months ago

3 Penny Stocks to Watch Now, 12/4/25

BQ


Jasper Therapeutics Transcript: Study Result

Dec 2, 2025, 8:00 AM EST - 5 months ago

Jasper Therapeutics Transcript: Study Result


Jasper Therapeutics reports data from ETESIAN Phase 1b study

2025-12-02T12:10:33.000Z - 5 months ago

Jasper Therapeutics reports data from ETESIAN Phase 1b study


Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)

2025-11-10T13:05:12.000Z - 6 months ago

Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)


Jasper Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences


Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

2025-09-19T10:00:28.000Z - 8 months ago

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43


Jasper Therapeutics price target lowered to $25 from $29 at UBS

2025-08-15T11:35:55.000Z - 9 months ago

Jasper Therapeutics price target lowered to $25 from $29 at UBS


Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

2025-08-13T20:35:13.000Z - 9 months ago

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)


Jasper Therapeutics Transcript: Study Update

Jul 7, 2025, 8:30 AM EDT - 11 months ago

Jasper Therapeutics Transcript: Study Update


Jasper Therapeutics Transcript: Status Update

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Jasper Therapeutics Transcript: Status Update


Jasper Therapeutics Transcript: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Transcript: Study Update


Jasper Therapeutics Transcript: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Result